CEO of drug maker Teva out ahead job cuts (Update)

October 30, 2013 by Tia Goldenberg
In this Wednesday, Oct. 16, 2013 file photo, trucks run past Teva Pharmaceutical Logistic Center in the town of Shoam, Israel. The chief executive of Israeli company Teva Pharmaceuticals Ltd. has resigned following a public uproar over a contentious restructuring plan set to cut thousands of jobs worldwide, Teva said Wednesday, Oct. 30. (AP Photo/Dan Balilty, File)

Israeli drug manufacturer Teva Pharmaceuticals Ltd. announced Wednesday its CEO had resigned, following a public uproar over a contentious restructuring plan set to cut thousands of jobs worldwide.

In a statement, Teva said its board of directors and President and CEO Jeremy Levin had agreed for him to step down. It gave no reason for the resignation, but the shakeup exposed cracks in the leadership of the world's largest generic drug maker.

The company's statement was quickly disputed. Late Wednesday, Levin told Israeli Channel 10 TV: "I did not resign. I did not choose to leave the company." He declined to comment further.

Teva's chairman Phillip Frost also told Channel 10: "It just got to the point where the slight differences couldn't be resolved. We thought it was better to part ways."

In an earlier statement announcing the resignation, Frost said the board and management were committed to "the planned acceleration of the company's cost reduction program."

Israeli media reported that Levin's downfall culminated months of tension between him and Frost. Those tensions intensified after the company said this month it would reduce its global workforce by about 10 percent—or 5,000 employees—as part of a restructuring plan.

The company has struggled in recent quarters with declining sales for both generic and brand-name drugs. The restructuring aims to slim the drug maker's business and make it more efficient.

Israeli Channel 2 TV reported this week that Levin and Frost fought over how to implement the restructuring. The planned layoffs set off an uproar and sense of betrayal in Israel, which has boosted Teva with years of grants, subsidies and tax breaks. Its success on the global stage has earned it the nickname "Israel's company." Some 800 Israeli employees are set to be laid off.

Under heavy public pressure, Levin agreed to meet with government officials and the powerful Histadrut labor union, vowing to re-evaluate the company's plan. Levin reportedly was intent on carrying out the layoffs gradually, whereas Frost and the board wanted them done immediately.

A letter obtained by Channel 2 said to be from the company's management and sent to the board spelled out the squabble.

"We acknowledge the commitments of members of the board to stockholders. Despite that, we urge the board to reconsider its interference in daily business, which in our opinion has become common in recent months, and prevents the management from managing Teva in an efficient way," the letter said.

In midday trading Wednesday on the Nasdaq Stock Market, the company's shares were down 7.2 percent to $38.08 apiece.

Levin is a former senior executive at U.S. drug maker Bristol-Myers Squibb who became CEO in 2012. Teva's board named Chief Financial Officer Eyal Desheh as an interim replacement and formed a committee to start searching for a permanent successor.

Analysts said Wednesday's resignation reflected a leadership crisis at the company.

"Teva, like most organizations, suffers from a surplus of management and a shortage of leadership, and that is a root problem endangering the future of the pharmaceutical giant," commentator Boaz Tamir wrote on the website of The Marker, an Israeli financial newspaper.

Explore further: Teva Pharma plans to cut about 5,000 employees (Update)

Related Stories

Teva Pharma plans to cut about 5,000 employees (Update)

October 10, 2013
Teva Pharmaceutical Industries Ltd. plans to cut about 5,000 employees mostly by the end of next year as part of a restructuring designed to slim the drugmaker's business and make it more efficient.

Israeli drug maker in uproar over planned layoffs

October 16, 2013
As the world's leading maker of generic drugs, Teva Pharmaceutical Industries Ltd. is a huge source of pride for Israel. Now, following an announcement of planned layoffs and revelations it enjoys sweeping tax exemptions, ...

Pfizer settles Protonix patent case for $2.15B

June 12, 2013
Two generic drugmakers will pay $2.15 billion to Pfizer and Takeda Pharmaceutical to settle a patent fight over the heartburn treatment Protonix.

Cisco to cut 4,000 jobs (Update)

August 14, 2013
Information technology giant Cisco announced Wednesday that it will cut 4,000 jobs, equal to five percent of its workforce.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.